These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 38471077)

  • 1. Systematic review of neurokinin-3 receptor antagonists for the management of vasomotor symptoms of menopause.
    Cieri-Hutcherson NE; Marji EK; Hutcherson TC
    Menopause; 2024 Apr; 31(4):342-354. PubMed ID: 38471077
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of fezolinetant for vasomotor symptoms in postmenopausal women: A systematic review and meta-analysis of randomized controlled trials.
    Akhtar SMM; Ali A; Khan MS; Khan V; Fareed A; Saleem SZ; Mumtaz M; Ahsan MN; Iqbal S; Asghar MS
    Int J Gynaecol Obstet; 2024 Sep; 166(3):969-983. PubMed ID: 38563867
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of Menopausal Vasomotor Symptoms With Fezolinetant, a Neurokinin 3 Receptor Antagonist: A Phase 2a Trial.
    Depypere H; Timmerman D; Donders G; Sieprath P; Ramael S; Combalbert J; Hoveyda HR; Fraser GL
    J Clin Endocrinol Metab; 2019 Dec; 104(12):5893-5905. PubMed ID: 31415087
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness and safety of fezolinetant in alleviating vasomotor symptoms linked to Menopause.: A systematic review and Meta-Analysis.
    Elnaga AAA; Alsaied MA; Elettreby AM; Ramadan A
    Eur J Obstet Gynecol Reprod Biol; 2024 Jun; 297():142-152. PubMed ID: 38640780
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and Safety of Fezolinetant for the Treatment of Menopause-Associated Vasomotor Symptoms: A Meta-analysis.
    Bonga KN; Mishra A; Maiti R; Padhy BM; Meher BR; Srinivasan A
    Obstet Gynecol; 2024 Mar; 143(3):393-402. PubMed ID: 38227939
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase 2b, randomized, placebo-controlled, double-blind, dose-ranging study of the neurokinin 3 receptor antagonist fezolinetant for vasomotor symptoms associated with menopause.
    Fraser GL; Lederman S; Waldbaum A; Kroll R; Santoro N; Lee M; Skillern L; Ramael S
    Menopause; 2020 Apr; 27(4):382-392. PubMed ID: 32102086
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of the neurokinin 3 receptor antagonist fezolinetant on patient-reported outcomes in postmenopausal women with vasomotor symptoms: results of a randomized, placebo-controlled, double-blind, dose-ranging study (VESTA).
    Santoro N; Waldbaum A; Lederman S; Kroll R; Fraser GL; Lademacher C; Skillern L; Young J; Ramael S
    Menopause; 2020 Dec; 27(12):1350-1356. PubMed ID: 32769757
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fezolinetant in the treatment of vasomotor symptoms associated with menopause.
    Depypere H; Lademacher C; Siddiqui E; Fraser GL
    Expert Opin Investig Drugs; 2021 Jul; 30(7):681-694. PubMed ID: 33724119
    [No Abstract]   [Full Text] [Related]  

  • 9. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Systematic review and network meta-analysis comparing the efficacy of fezolinetant with hormone and nonhormone therapies for treatment of vasomotor symptoms due to menopause.
    Morga A; Ajmera M; Gao E; Patterson-Lomba O; Zhao A; Mancuso S; Siddiqui E; Kagan R
    Menopause; 2024 Jan; 31(1):68-76. PubMed ID: 38016166
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fezolinetant: a novel nonhormonal therapy for vasomotor symptoms due to menopause.
    Roberts MZ; Andrus MR
    Expert Opin Pharmacother; 2024 Jun; 25(9):1131-1136. PubMed ID: 38953697
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of neurokinin 3 receptor antagonist fezolinetant on hot flash-like symptoms in ovariectomized rats.
    Tahara A; Takamatsu H; Ohtake A; Tanaka-Amino K; Kaku S
    Eur J Pharmacol; 2021 Aug; 905():174207. PubMed ID: 34048742
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of fezolinetant, a neurokinin-3 antagonist, in treating vasomotor symptoms in postmenopausal women: A systematic review and meta-analysis.
    Rahman UA; Kashif TB; Usman M; Rana M; Hasanain M; Anjum MU; Cheema HA; Jaffar H; Bhattarai P
    Medicine (Baltimore); 2023 Dec; 102(50):e36592. PubMed ID: 38115258
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of fezolinetant for moderate to severe vasomotor symptoms associated with menopause among women in East Asia: a phase 3 randomized study (MOONLIGHT I).
    Ruan X; Bai W; Ren M; Kim T; Lee JY; Chuang FC; Wang PH; He W; Ma X; Miyazaki K; Song N; Wang X; Yu Q
    J Int Med Res; 2024 May; 52(5):3000605241247684. PubMed ID: 38818888
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fezolinetant for the treatment of vasomotor symptoms associated with menopause: a meta-analysis.
    Chavez MP; Pasqualotto E; Ferreira ROM; Hohl A; de Moraes FCA; Schmidt PHS; Rodrigues ALSO; de Sa JR
    Climacteric; 2024 Jun; 27(3):245-254. PubMed ID: 38619017
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of elinzanetant, a selective neurokinin-1,3 receptor antagonist for vasomotor symptoms: a dose-finding clinical trial (SWITCH-1).
    Simon JA; Anderson RA; Ballantyne E; Bolognese J; Caetano C; Joffe H; Kerr M; Panay N; Seitz C; Seymore S; Trower M; Zuurman L; Pawsey S
    Menopause; 2023 Mar; 30(3):239-246. PubMed ID: 36720081
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and Safety of Fezolinetant in Moderate to Severe Vasomotor Symptoms Associated With Menopause: A Phase 3 RCT.
    Johnson KA; Martin N; Nappi RE; Neal-Perry G; Shapiro M; Stute P; Thurston RC; Wolfman W; English M; Franklin C; Lee M; Santoro N
    J Clin Endocrinol Metab; 2023 Jul; 108(8):1981-1997. PubMed ID: 36734148
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design of OASIS 1 and 2: phase 3 clinical trials assessing the efficacy and safety of elinzanetant for the treatment of vasomotor symptoms associated with menopause.
    Pinkerton JV; Simon J; Panay N; Seitz C; Parke S; Caetano C; Mellinger U; Haseli Mashhadi N; Haberland C; Atanackovic G; Holz C; Mao G; Morrison M; Nisius S; Schaefers M; Zuurman L
    Menopause; 2024 Jun; 31(6):522-529. PubMed ID: 38564691
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term safety of fezolinetant in Chinese women with vasomotor symptoms associated with menopause: the phase 3 open-label MOONLIGHT 3 clinical trial.
    Yu Q; Ming F; Ma J; Cai Y; Wang L; Ren M; Zhang J; Ma X; Miyazaki K; He W; Wang X
    J Int Med Res; 2024 May; 52(5):3000605241246624. PubMed ID: 38818887
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fezolinetant treatment of moderate-to-severe vasomotor symptoms due to menopause: effect of intrinsic and extrinsic factors in two phase 3 studies (SKYLIGHT 1 and 2).
    Santoro N; Nappi RE; Neal-Perry G; English M; King DD; Yamaguchi Y; Ottery FD
    Menopause; 2024 Apr; 31(4):247-257. PubMed ID: 38517210
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.